Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis

Combination Deferasirox and Deferiprone for Severe Iron Overload in Thalassemia

NCT01709032 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload.

NCT01250951 ·Status: COMPLETED ·Phase: PHASE4

Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)

NCT00171301 ·Status: COMPLETED ·Phase: PHASE4

Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients

NCT00303329 ·Status: COMPLETED ·Phase: PHASE2

Deferasirox BID (Twice a Day) in Transfusion Dependent Thalassemia Patients With Inadequate Response to High Doses

NCT01948817 ·Status: WITHDRAWN ·Phase: PHASE2

Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload

NCT00560820 ·Status: COMPLETED ·Phase: PHASE1

Safety and Efficacy of Deferasirox in Combination With Desferoxamine in β-thalassaemia Patients With Severe Cardiac Iron Overload

NCT01459718 ·Status: TERMINATED ·Phase: PHASE2

Efficacy and Safety Study of Deferasirox in Patients With Non-transfusion Dependent Thalassemia

NCT01709838 ·Status: COMPLETED ·Phase: PHASE4

Study Using Deferiprone Alone or in Combination With Desferrioxamine in Iron Overloaded Transfusion-dependent Patients

NCT00349453 ·Status: COMPLETED ·Phase: PHASE2

Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload

NCT00600938 ·Status: COMPLETED ·Phase: PHASE2

Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients

NCT00110617 ·Status: COMPLETED ·Phase: PHASE2

A Study Assessing the Efficacy and Safety of Deferasirox in Patients With Transfusion-dependent Iron Overload

NCT00171821 ·Status: COMPLETED ·Phase: PHASE3

Iron Balance Study of DFO and GT56-252 in Patients With Transfusional Iron Overload Secondary to Beta-Thalassemia

NCT00069862 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Retrospective Evaluation of Adult and Pediatric Transfusion-dependent Patients Treated With Deferasirox Therapy

NCT01874405 ·Status: COMPLETED

Clinical Trial of Deferasirox Combination Treatment With Deferiprone In Thalassaemia Patients

NCT02198508 ·Status: COMPLETED ·Phase: NA

Extension Study of Iron Chelation Therapy With Deferasirox in Patients With Transfusional Iron Overload

NCT00379483 ·Status: COMPLETED ·Phase: PHASE2

Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases

NCT00115349 ·Status: TERMINATED ·Phase: PHASE2

Evaluating the Safety and Effectiveness of Decitabine in People With Thalassemia Intermedia

NCT00661726 ·Status: COMPLETED ·Phase: PHASE2

Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary Hemochromatosis

NCT00395629 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients

NCT00110266 ·Status: COMPLETED ·Phase: PHASE2

Combination Iron Chelation Therapy

NCT00004982 ·Status: COMPLETED ·Phase: PHASE1

Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis (HH)

NCT03203850 ·Status: TERMINATED ·Phase: PHASE2

Iron Balance Study of Deferasirox, Deferoxamine and the Combination of Both

NCT00738413 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment

NCT00447694 ·Status: COMPLETED ·Phase: PHASE2

Efficacy Study in Removing Excess Iron From the Heart

NCT00105495 ·Status: COMPLETED ·Phase: PHASE4